.svg)
Introduction
01
A forward-looking cooperation: Fette Pharma and Cannbit Pharmaceuticals
With the Israeli company Cannbit, Fette Pharma has had a partner at its side since 2019 that is playing a pioneering role in the era of modern medical cannabis.
For many years, Israel has been one of the leading nations in research into the mechanisms of action of medicinal cannabis. Thanks to the decades-long relationship that Fette Pharma has with Israel as a pharmaceutical and technology location through the distribution of natural and at the same time innovative medicinal products, it was possible to enter into a cooperation with one of the leading cannabis producers in Israel at an early stage. This enables Fette Pharma to import qualitatively unique medical cannabis from Israel to Germany and to participate in innovative research projects and developments, among others of prescription drugs. Thus, Fette Pharma seizes the opportunity to bring the great lead that Israel has in the research and development of medical cannabis to Germany and to further expand it in the context of new projects.
The cannabis plant is known for its pain-reducing effect – today, inflammatory, autoimmunological and neurological diseases are also increasingly coming into focus, in which cannabis or its derivatives are used. The basis for the current interest in the cannabis plant in medical applications is the human endocannabinoid system: an important biochemical-endogenous system involved in a variety of physiological functions, discovered by the Israeli research team led by Prof. Raphael Mechoulam in 1992. The work published by Prof. Mechoulam consolidates findings from basic and applied clinical research of the last 50 years. He is considered a pioneer and trailblazer of modern cannabis research and is a worldwide recognized authority on the clinical use of medical cannabis.
Find out more
Advantages of the cooperation
02
Advantages of the cooperation between Fette Pharma and Cannbit Pharmaceuticals
Thanks to the cooperation of Fette Pharma with the Israeli company Cannbit, it is possible to use the scientific and clinical wealth of experience also in Germany. The background of the unique product quality and the outstanding services for physicians and patients are*:
- Over 16 years of experience in genetic research and development of Cannabis
- Over 35 clinical and preclinical studies
- 20 publications of studies in leading scientific journals
- Information and data from more than 40,000 patients on treatment options with medical cannabis
- State-of-the-art production facilities and processes that guarantee products of the highest and consistent quality
The plantations of Cannbit, Fette Pharma's cooperation partner, are located in Israel on the Dead Sea. In this magical place, 450 meters below sea level, Cannbit not only researches and tests innovative, forward-looking cultivation methods and processes, but has created a unique ecosystem that puts research at the center - on the one hand in the context of clinical trials, and on the other in the form of genetic research and development for new, innovative cannabis varieties that precisely meet actual medical needs. This is how the genetic uniqueness of Cannbit's cannabis strains is guaranteed today and will continue to be so in the future.
*Relatingto the studies and data Cannbit can access through the acquisition of Tikun Olam Israel.
Find out more
